Prosecution Insights
Prosecution Insights
Tech Center 4100 • Art Units: 1614 1626 1628 1629 1642 1691 4100
This examiner grants 80% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18523284 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | Non-Final OA | Genentech, Inc. |
| 18850640 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | Non-Final OA | FLAGSHIP PIONEERING INNOVATIONS VI, LLC |
| 18827510 | KRAS G12D MODULATING COMPOUNDS | Non-Final OA | Gilead Sciences, Inc. |
| 18900035 | TREATMENT OF NEURODEGENERATIVE DISEASES VIA ADMINISTRATION OF BUNTANETAP AND A PHOSPHODIESTERASE INHIBITOR | Non-Final OA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
| 18849133 | THERAPEUTIC OR PROPHYLACTIC MEDICINE FOR FRAGILE X SYNDROME | Non-Final OA | Kyoto University |
| 18827269 | Kinase Inhibitors | Non-Final OA | Incyte Corporation |
| 18821138 | BICYCLIC COMPOUNDS AS INHIBITORS OF WRN | Non-Final OA | Incyte Corporation |
| 18777765 | NOVEL METHODS | Non-Final OA | INTRA-CELLULAR THERAPIES, INC. |
| 18661922 | FLEX-NUCLEOSIDE ANALOGUES, NOVEL THERAPEUTICS AGAINST FILOVIRUSES AND FLAVIVIRUSES | Non-Final OA | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY |
| 18902773 | TRYPTAMINE PRODRUGS | Non-Final OA | Reunion Neuroscience, Inc. |
| 18764647 | METHOD FOR TREATMENT OF PARKINSON'S DISEASE | Non-Final OA | NeuroDerm, Ltd. |
| 18624508 | METHODS OF TREATING HEART FAILURE WITH REDUCED EJECTION FRACTION USING MODIFIED FORMS OF TRIMETAZIDINE | Non-Final OA | IMBRIA PHARMACEUTICALS, INC. |
| 18289274 | ANTIDEPRESSANT AND ANXIOLYTIC SUBSTITUTED CINNAMAMIDE COMPOUND | Non-Final OA | TASLY PHARMACEUTICAL GROUP CO., LTD. |
| 18287329 | GOLEXANOLONE FOR USE IN THE TREATMENT OF FATIGUE OR COGNITIVE IMPAIRMENT IN LIVER DISEASE PATIENTS | Final Rejection | Umecrine Cognition AB |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy